OLIMAB

Olimab Injection 60mg contains the active ingredient Denosumab, a medication primarily prescribed for the treatment of osteoporosis, a condition defined by weakened and brittle bones. Beyond osteoporosis, it also plays a crucial role in preventing bone-related complications in patients afflicted with certain types of cancer, including multiple myeloma and those with bone metastases. The mechanism by which Olimab 60mg Injection achieves its effects involves inhibiting a specific protein known as RANK ligand. This protein is a key mediator in the process of bone tissue breakdown. By blocking the action of RANK ligand, the injection helps to preserve bone mass and strength. Clinical studies have demonstrated its significant ability to increase bone density, which, in turn, effectively reduces the risk of fractures in various patient populations, particularly postmenopausal women suffering from osteoporosis and individuals experiencing bone loss due to cancer. For patients with moderate renal impairment, careful and close monitoring of their kidney function may be necessary throughout the course of treatment to ensure safety and efficacy. Furthermore, Olimab 60mg injection can be a valuable therapeutic option for treating osteoporosis in both postmenopausal women and men who are identified as being at a high risk of experiencing fractures.

There are specific circumstances under which Olimab 60mg Injection should not be used. It is contraindicated in individuals who have a known hypersensitivity or allergic reaction to Denosumab or any other components of the injection. To ensure optimal bone health during treatment, it is essential that patients receive adequate supplementation with both calcium and vitamin D. Importantly, this medication is not approved for use in children and adolescents; its safety and effectiveness have not been established in pediatric populations, making its use contraindicated for individuals under 18 years of age. Additionally, caution is advised when administering this medication to individuals with pre-existing hypoparathyroidism, a condition characterized by abnormally low levels of parathyroid hormone, as their physiological response may require careful management.